Shield Therapeutics (FRA:1JS) Liabilities-to-Assets : 1.23 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Shield Therapeutics Liabilities-to-Assets?

Shield Therapeutics FRA:1JS Liabilities-to-Assets is 1.23 as of Dec. 2025. The stock has 5 warning signs investors should review.

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Shield Therapeutics's Total Liabilities for the quarter that ended in Dec. 2025 was €68.57 Mil. Shield Therapeutics's Total Assets for the quarter that ended in Dec. 2025 was €55.69 Mil. Therefore, Shield Therapeutics's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2025 was 1.23.

Shield Therapeutics  (FRA:1JS) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.

Shield Therapeutics Liabilities-to-Assets Related Terms

Shield Therapeutics Liabilities-to-Assets Historical Data

* Premium members only.

The historical data trend for Shield Therapeutics's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shield Therapeutics Liabilities-to-Assets Chart

Shield Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Liabilities-to-Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.08 0.75 0.69 1.02 1.23

Shield Therapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Liabilities-to-Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.69 0.99 1.02 1.24 1.23

FRA:1JS vs ZTS, UTHR, VTRS: Liabilities-to-Assets Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Shield Therapeutics's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shield Therapeutics Liabilities-to-Assets vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shield Therapeutics's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where Shield Therapeutics's Liabilities-to-Assets falls into.


Shield Therapeutics Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

Shield Therapeutics's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2025 is calculated as:

Liabilities-to-Assets (A: Dec. 2025 )=Total Liabilities/Total Assets
=68.569/55.694
=1.23

Shield Therapeutics's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2025 is calculated as

Liabilities-to-Assets (Q: Dec. 2025 )=Total Liabilities/Total Assets
=68.569/55.694
=1.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Liabilities-to-Assets →
What does a Liabilities-to-Assets of 1.23 mean?
Shield Therapeutics (FRA:1JS) has a Liabilities-to-Assets of 1.23 as of Dec. 2025. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Shield Therapeutics and its competitors.
Is Shield Therapeutics' Liabilities-to-Assets too high?
Shield Therapeutics' current Liabilities-to-Assets is 1.23.
How does Shield Therapeutics' Liabilities-to-Assets compare to ZTS and UTHR?
Shield Therapeutics' Liabilities-to-Assets of 1.23 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Liabilities-to-Assets for a Drug Manufacturers company?
A good Liabilities-to-Assets depends on the Drug Manufacturers industry context. However, Liabilities-to-Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Liabilities-to-Assets mean?
A high Liabilities-to-Assets can signal that a stock is expensive relative to its fundamentals. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Shield Therapeutics and its competitors. Shield Therapeutics's current Liabilities-to-Assets is 1.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shield Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Shield Therapeutics (FRA:1JS) is currently considered Possible Value Trap. The stock's GF Value™ is €0.10, compared to a current price of €0.07 — trading 32% below its estimated fair value. The current Liabilities-to-Assets is 1.23. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Liabilities-to-Assets calculated?
Liabilities-to-Assets is calculated from a company's financial statements. For Shield Therapeutics (FRA:1JS), the current Liabilities-to-Assets is 1.23 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Shield Therapeutics Business Description

Other Exchanges SHIEF:USASTX:UK
Address Gateshead Quays, Northern Design Centre, Baltic Business Quarter, Newcastle, GBR, NE8 3DF
Shield Therapeutics PLC is a commercial-stage specialty pharmaceutical company that delivers ACCRUFeR/FeRACCRU (ferric maltol), a differentiated pharmaceutical product, to address the unmet need for patients suffering from iron deficiency, with or without anemia. The company has launched ACCRUFeR in the U.S. Outside of the U.S., it has licensed the rights to specialty pharmaceutical companies. FeRACCRU is commercialised in the UK, the European Union, and Canada, with marketing rights in Australia and New Zealand. The company's operating segments are: FeRACCRU, which generates the maximum revenue, and PT20. Geographically, it generates maximum revenue from the U.S., and the rest from the Netherlands, Canada, Japan, and South Korea.